Cochrane · systematic review · CD009904
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
Saglimbene, VM, Palmer, SC, Ruospo, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (CKD)
Population: CKD patients (any stage) treated for anaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | NR | No studies |
Epoetin | no estimate extracted | 5 studies · 1846 participants | Low |
Darbepoetin | no estimate extracted | 5 studies · 1657 participants | Low |
CERA Q4W | no estimate extracted | 2 studies · 822 participants | Low |
CERA higher dose | no estimate extracted | 1 study · 42 participants | Low |
Hypertension | no estimate extracted | NR | No studies |
PLACEBO | no estimate extracted | 1 study · 235 participants | Low |